Kaitlyn D’Onofrio

DocwireNews

<a href="https://www.prnewswire.com/news-releases/us-fda-approves-supplemental-new-drug-application-snda-for-erleada-apalutamide-for-the-treatment-of-patients-with-metastatic-castration-sensitive-prostate-cancer-mcspc-300920333.html">The Food &amp; Drug Administration (FDA)</a> recently expanded its approval of <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-expands-approval-for-erleada-in-prostate-cancer/">apalutamide (Erleada)</a> to be included as an add-on treatment of metastatic castration-sensitive <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/enzalutamide-can-improve-outcomes/">prostate cancer</a> (mCSPC) in conjunction with androgen deprivation therapy (ADT). Erleada is manufactured by Janssen, of Johnson &amp; Johnson. The drug was approved for the treatment of nonmetastatic castration-resistant prostate cancer in 2018. The most recent indication follows the phase III TITAN trial, the results of which were published in the <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1903307">New England Journal of Medicine</a>.
The drug will likely compete against enzalutamide (Xtandi, from Pfizer and Astellas) with this new indication. Xtandi is currently indicated for nonmetastatic castration-resistant prostate cancer. It was recently granted priority review by the FDA to determine if it is qualified to treat mCSPC, with a decision expected in 2020.
Efficacy/Outcomes
In the TITAN trial, patients were randomized to receive apalutamide 240 mg/day or placebo in combination with ADT. The primary outcomes were progression-free survival (PFS) and overall survival (OS). After a median 22.7 months of follow-up, the rate of PFS was 68.2% in the apalutamide group and 47.5% in the placebo group, and the rates of OS were 82.4% and 73.5%, respectively.
Enzalutamide was tested in <a href="https://ascopubs.org/doi/full/10.1200/JCO.19.00799">ARCHES</a>, also a phase III study. Patients were randomized to receive enzalutamide 160 mg/day or placebo in combination with ADT. The primary outcome was PFS. The researchers reported: “As of October 14, 2018, the risk of radiographic progression or death was significantly reduced with enzalutamide plus ADT versus placebo plus ADT (hazard ratio, 0.39; 95% CI, 0.30 to 0.50; P &lt; .001; median not reached v 19.0 months).”
Enzalutamide was also tested in <a href="https://www.nejm.org/doi/10.1056/NEJMoa1903835">ENZAMET</a>, another randomized, phase III study. Patients received testosterone suppression plus either enzalutamide or a standard nonsteroidal antiandrogen therapy. The primary outcome was OS, and one of the secondary outcomes was PFS. After a median follow-up of 34 months, there were 102 deaths in the enzalutamide group and 143 in the standard-care group (HR, 0.67; 95% confidence interval [CI], 0.52 to 0.86; P = 0.002). Overall three-year survival estimates were 80% in the enzalutamide group and 72% in the standard-care group. Enzalutamide was superior in PFS (174 and 333 events, respectively; HR, 0.39; P &lt; 0.001).
Safety
In the TITAN trial, the rates of grade 3 or 4 adverse events were similar in the apalutamide (42.2%) and placebo (40.8%) groups; the study authors noted that the apalutamide group had a higher rate of rash.
The ARCHES trial also found a similar rate of grade 3 or greater adverse events in the treatment (24.3%) and placebo (25.6%) groups.
In ENZAMET, patients were more likely to discontinue enzalutamide due to adverse events than standard care. Enzalutamide patients were more prone to fatigue, and there were seven seizures in the enzalutamide group and zero in the standard care group.
Cost
A 30-day supply of <a href="https://www.drugs.com/price-guide/erleada">Erleada</a> costs an estimated $12,297. A one-month supply includes 120 60-mg pills. The recommended daily dose is 240 mg.
A 30-day supply of <a href="https://www.drugs.com/price-guide/xtandi">Xtandi</a> costs an estimated $12,066. A one-month supply includes 120 40-mg pills. The recommended daily dose is 160 mg.

Andrew Moreno

Genetic Classification Model Differentiates MDS Stem, Progenitor Cells from Healthy Bone Marrow

ASH 2024

Cecilia Brown

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line Treatment of ES-SCLC

Small Cell Lung Cancer

Genetic Study Uncovers Potential Therapy-Actionable Transcription Factors in MDS

Latest News

Erleada vs. Xtandi: A Comparison of Prostate Cancer Drugs

Oncology

The Food &amp; Drug Administration (FDA) recently expanded its approval of apalutamide (Erleada) to be included as an add-on treatment of metastatic castration-sensitive ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe